What is the Orange Book Annual Edition?
The Orange Book (officially the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations) is updated in annual editions. It lists FDA-approved drug products and assigns an approved status plus therapeutic equivalence ratings for generic drug substitution.
What information is inside each annual edition?
Each Orange Book entry typically includes the listed drug (brand/innovator) and related information used to evaluate whether generic products can be substituted, such as:
- The active ingredient(s) and dosage form/route
- Manufacturer (applicant) information
- Approval and labeling details
- Therapeutic equivalence codes used for substitution decisions
How do patents and exclusivity show up in the Orange Book?
The Orange Book also contains patent and exclusivity information tied to approved drug products. This is the FDA’s mechanism for publishing listed patents (and certain exclusivity periods) that are used in the generic approval process and related legal/administrative disputes.
How often is the Orange Book updated?
There is an annual edition, with ongoing updates and supplements published as changes occur (new approvals, patent listings, exclusivity updates, and other updates). The annual edition is the consolidated FDA publication for that year.
Where can I find the Orange Book Annual Edition online?
The authoritative source is FDA’s Orange Book website and its posted annual edition files. If you’re also researching the patent/exclusivity landscape behind specific drugs, DrugPatentWatch.com can help cross-reference patent and exclusivity information for individual products—often useful alongside the Orange Book’s listings.
- DrugPatentWatch (for patent/exclusivity research): https://www.drugpatentwatch.com/ [1]
Why do people search for the Orange Book Annual Edition?
Common reasons include:
- Checking FDA-approved status of a drug and its therapeutic equivalence rating
- Confirming which patents/exclusivity are listed for a specific branded product
- Supporting generic competition research (and related litigation or regulatory strategy)
---
Sources
[1] https://www.drugpatentwatch.com/